Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Pelt – page 37

870 clinical trials in Pelt, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Pelt at a glance
870
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

870 trials in Pelt

Open in trial search

SARS-CoV-2 test positive

Not yet recruiting

Study on Montelukast for COVID-19 Patients at Higher Risk of Complications in the Community

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Montelukast
  • Sponsor:Universiteit Maastricht

Ischaemic stroke+1

Not yet recruiting

Study on Stopping Atorvastatin in Frail Patients Aged 70+ with Recent Ischemic Stroke or Transient Ischemic Attack

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:65+ years
  • Substances:Atorvastatin
  • Sponsor:Amsterdam UMC Stichting

Cholangiocarcinoma

Not yet recruiting

Study of Ivosidenib for Patients with Previously Treated Advanced or Metastatic Cholangiocarcinoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ivosidenib
  • Sponsor:Servier Affaires Medicales

Malignant melanoma

Not yet recruiting

Study Comparing MK-7684A (Vibostolimab and Pembrolizumab) with Pembrolizumab for Adults and Children with High-Risk Melanoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer

Not yet recruiting

Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Eli Lilly & Co.

Acute myeloid leukaemia

Not yet recruiting

Study on the Safety of Ivosidenib and Azacitidine for Adults with Newly Diagnosed IDH1m Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Servier Affaires Medicales

Renal cell carcinoma

Not yet recruiting

Study comparing XL092 plus nivolumab versus sunitinib for patients with advanced or metastatic non-clear cell kidney cancer

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Exelixis Inc.

Dementia Alzheimer's type

Not yet recruiting

Study on JNJ-64042056 for Preclinical Alzheimer's Disease in Patients

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:JNJ-64042056
  • Sponsor:Janssen Cilag International

Colorectal cancer+1

Not yet recruiting

Study on Irinotecan and mFOLFOX4-Bevacizumab for Patients with Resectable Colorectal Peritoneal Metastases

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Colitis ulcerative

Not recruiting

Evaluation of Long-Term Efficacy and Safety of Obefazimod as Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Guselkumab and Ustekinumab for Patients with Moderate to Severe Crohn's Disease

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Hypertension

Not recruiting

Study on Lorundrostat for Patients with Uncontrolled and Resistant Hypertension

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Lorundrostat
  • Sponsor:Mineralys Therapeutics Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Pelt

What the registry says about research in the country

01 Multiple Sclerosis Research

Extensive research focusing on relapsing forms of multiple sclerosis, evaluating novel therapeutic approaches and comparing treatment efficacies. Studies investigate various medications including frexalimab and remibrutinib against established treatments.

  • Relapsing MS Therapies
  • Disease Progression Analysis
  • Treatment Comparison Studies

Several trials aim to assess reduction in relapse frequency and improvement in patient outcomes.

02 Progressive MS Studies

Dedicated research into primary progressive multiple sclerosis (PPMS) and secondary progressive forms, exploring innovative treatments and their impact on disease progression. Studies evaluate higher-dose protocols and long-term effectiveness.

  • Disability Progression Markers
  • Novel Treatment Approaches
  • Long-term Safety Assessments

Focus on developing treatments to delay disability progression and improve patient mobility.

03 Advanced Therapeutic Studies

Investigation of innovative treatment modalities including BTK inhibitors and combination therapies. Research includes assessment of brain remyelination and neurodegeneration markers.

  • Biomarker Analysis
  • Pharmacokinetic Studies
  • Safety Monitoring

Comprehensive evaluation of new therapeutic approaches using advanced imaging and clinical assessments.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.